Tyra Biosciences (NASDAQ:TYRA) Given “Buy” Rating at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $45.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 24.38% from the company’s current price.

Several other research firms also recently issued reports on TYRA. Jefferies Financial Group upped their price objective on shares of Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, February 3rd. Canaccord Genuity Group assumed coverage on shares of Tyra Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $50.00 target price for the company. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Monday, April 20th. Finally, Piper Sandler increased their target price on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Tyra Biosciences Price Performance

NASDAQ TYRA opened at $36.18 on Thursday. Tyra Biosciences has a 1 year low of $8.75 and a 1 year high of $40.65. The company has a market capitalization of $2.15 billion, a PE ratio of -18.00 and a beta of 0.79. The company has a fifty day moving average of $36.06 and a two-hundred day moving average of $28.77.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, research analysts expect that Tyra Biosciences will post -2.42 earnings per share for the current year.

Insider Transactions at Tyra Biosciences

In related news, Director Gilla Kaplan sold 14,295 shares of the stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the transaction, the director directly owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. HighVista Strategies LLC raised its holdings in Tyra Biosciences by 163.6% during the third quarter. HighVista Strategies LLC now owns 65,812 shares of the company’s stock worth $921,000 after purchasing an additional 40,850 shares in the last quarter. Commodore Capital LP increased its holdings in Tyra Biosciences by 8.9% in the third quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after buying an additional 275,000 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in Tyra Biosciences in the third quarter valued at about $2,612,000. Eversept Partners LP increased its holdings in Tyra Biosciences by 2.1% in the fourth quarter. Eversept Partners LP now owns 278,564 shares of the company’s stock valued at $7,323,000 after buying an additional 5,858 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new position in Tyra Biosciences in the fourth quarter valued at about $10,476,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.